Inhibrx Biosciences Inc. (NASDAQ:INBX)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
INBX Weekly Chart

Old Forum Content for INBX

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • MongosPawn: @woodman $MREO $SNY $INBX Just seeing this post now. Thanks again for all the great info. I did add some last week. Am now at about 35% of a typical stock full position, but for my bio-techs I'm at about 70% of a full bio position. FWIW.
  • woodman: @sierramp $MREO $SNY $INBX - I can't emphasize enough that biotech investing is brutal. too often indiscriminately cruel, and can make anyone look like a fool in the snap of a finger, so it's important to invest at your comfort level should things go south.
  • woodman: $MREO @sierramp @MongosPawn @Onthemark et al. - this $2.2 billion deal for $SNY to buy $INBX's AATD drug candidate bodes well for $MREO. See https://inhibrx.investorroom.com/2024-01-23-Inhibrx-Announces-Sale-of-INBRX-101-to-Sanofi-for-an-aggregate-value-of-up-to-2-2B MREO's drug candidate for AATD lung disease (Alvelestat) has two Phase 2 trials completed with over 160 patients recruited and has a validated path forward to Phase 3 with potential partnering on the horizon (also being tested for Bronchitis Obliterans Syndrome) is further along than $INBX's just-purchased drug (in Phase 1 single arm trial with 31 patients enrolled and a confused path forward). MREO also has a Phase 3 study of setrusumab (data due end of 1Q) for treatment of Osteogenesis Imperfecta (OI - bone deformities and weak bones) These drugs are multi-billion dollar opportunities, especially AATD-LD. At $471 mil market cap, MREO looks cheap.
  • woodman: $MREO $SNY $INBX - I'm kicking myself for failing to add to $MREO this morning. I had it teed up for an add around $3.00, but didn't do it.
  • sierramp: @woodman $MREO $SNY $INBX That's what caused the beautiful move in $MREO today, nice! Thank you. I was looking for news on $MREO but didn't look for collateral stock news. You have a very good nose for these stocks. Too bad you missed your buy point but I suspect you have a good position. I've only got about a quarter of a full position but because of the volatility of biotech, that is my comfort level. Thank you for letting us know what is happening. Hopefully we'll see more of this action.
  • woodman: @Babutters $INBX - Hi, I just saw your note of thanks from yesterday. I'm glad the INBX trade worked for you. It had a pretty good 3-day run, now seems to be taking a little flag-like breather. Separately, I never got around to providing a list of the #Gene #Car-T stocks that I said yesterday I'd post, many of which, unsurprisingly like #Biotech generally, are doing well. I'll get around to it eventually. :-)
  • Babutters: @woodman $INBX #Gene #Car-T #Biotech you didn’t 😉, but it’s all good. We all have lives and plenty of goodness in the forum to look at. Speaking of cars and since this is #OT I’m watching the Austrian GP quali and drinking a cold one after a really good week. Have a great weekend!
  • woodman: @Babutters $INBX #Gene #Car-T #Biotech #OT - I suspect you are a fan of Netflix's Formula 1: Drive to Survive. It's an oddly captivating show for me. I do like cars but I'm not nearly as magnetized to them as I was in my youth. Still, that show is fun to watch.
  • woodman: And to keep things in one place, here are other #Biotech stocks I mentioned a couple days ago. $YMAB $AVXL $XNCR $NRIX $CHRS $ZNTL $OMGA $DBTX $WVE $INBX.
  • Babutters: @woodman $YMAB $AVXL $XNCR $NRIX $CHRS $ZNTL $OMGA $DBTX $WVE $INBX #Biotech yessir. Love the show although wasn’t impressed with the last season (if you watched the F1 season you would understand where I’m coming from). I used your list to create a new list on my YF account. Good stuff - and more studying.
  • Docoof: @woodman $YMBA $AVXL $XNCR $NRIX $CHRS $ZNTL $OMGA $DBTX $WVE $INBX #biotech Thank you for posting this—after hours I review all your very helpful posts. $YMBA (typo) = $YMAB.
  • woodman: @Docoof $YMBA $AVXL $XNCR $NRIX $CHRS $ZNTL $OMGA $DBTX $WVE $INBX $YMAB #biotech - Thank you for the correction! Sorry I've not been so engaged the last several weeks. I've largely been taking a break during the Market malaise, attending to personal and professional matters, enjoying time with my family, and getting some golf time in as well. I am trading here and there, holding very little (currently just a few biotech or related holdings), but now trying to re-engage more so as to not be totally tuned out. Eventually, the tide will change and I don't want to be completely disengaged. But on the whole, I'm not very active in this market.
  • Babutters: @woodman $CRSP #Biotech #Gene #Car-T I entered $INBX this morning on a day trade after seeing your AH post. Closed EOD (couldn’t stare at phone). Passing over a thank you.
  • woodman: Some nice #biotech movers: For example: $YMBA $AVXL $XNCR $NRIX $CHRS $ZNTL $OMGA $DBTX $WVE $INBX. Many others.
Visit the Trading Forum to join in the discussion.
Stock Price $15.52
Change 1.24%
Volume 55,395

Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.

Request Video of INBX
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!